key: cord-0933084-v2q8jxjr
authors: Cavalli, Giulio; Dagna, Lorenzo
title: Effect of anakinra in COVID-19 – Authors' reply
date: 2020-07-24
journal: Lancet Rheumatol
DOI: 10.1016/s2665-9913(20)30236-8
sha: ef46d9402c3d6eed88a09ad2f4ed415bb1f88f63
doc_id: 933084
cord_uid: v2q8jxjr

nan

Authors' reply

We thank Emma Kooistra and col leagues for their interest in our study. 1 They raise several interesting points. A certain degree of difference in baseline characteristics is an inherent limitation of cohort studies. Kooistra and colleagues point out a between group difference in age, which we agree is a risk factor for poorer outcomes and might have biased our results in favour of the anakinra group. 1 However, they neglect other variables that would be expected to have the opposite effect, including more severe impairment in respiratory function in patients receiving highdose anakinra, a feature that is also indicative of clinical severity and is associated with poorer outcomes. 1 Kooistra and colleagues also dis cuss serum ferritin, and correctly state that serum ferritin concentrations higher than 2000 ng/mL increase the likelihood of macrophage activa tion syndrome (MAS). 2 3 and in instructing use of anakinra, which has emerged as a promising therapy for COVID19 in several publications following our first report. 4, 5 However, one should be mindful that hyperinflammation in COVID19 does not equate to MAS; the validity of the 2000 ng/mL ferritin threshold in COVID19 is not clearcut.

Concerning the statistical design of our study, we agree with Kooistra and colleagues that propensity score matching is a preferable option for cor recting unavoidable differences in clinical features of patients in cohort studies, outside a controlled trial setting. However, the size of our cohorts at the time that we started our study precluded effective deployment of propensity score matching. We welcome evidence generated using this statistical approach in future studies, as well as data from randomised clini cal trials. If data from randomised trials become available, these will super sede our findings. However, although superior to observational studies at generating evidence, randomised trials are not as pragmatic under truly emergency circumstances. Obser vational studies informed clinical deci sion making at the cusp of the COVID19 pandemic. Several ongoing clinical trials will follow and generate controlled data, some of which might only become available after the end of the pandemic, with little or no impact on patient management.

We declare no competing interests.

Allergy and Rare Diseases, IRCCS San Raffaele Scientific Institute

Interleukin1 blockade with highdose anakinra in patients with COVID19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study

Immune mechanisms of pulmonary intravascular coagulopathy in COVID19 pneumonia

COVID19: consider cytokine storm syndromes and immunosuppression

Anakinra for severe forms of COVID19: a cohort study

Favorable anakinra responses in severe Covid19 patients with secondary hemophagocytic lymphohistiocytosis